DCF Advisers’s Alexion Pharmaceuticals ALXN Stock Holding History

DCF Advisers’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-6,000	Closed	-$1.1M	–	105
2021 Q2	$1.1M	Sell	6,000 -6,000	-50%	-$1.03M	0.39%	49
2021 Q1	$1.83M	Sell	12,000 -3,000	-20%	-$464K	0.8%	33
2020 Q4	$2.34M	Buy	15,000 +2,000	+15%	+$257K	0.97%	33
2020 Q3	$1.49M	Hold	13,000	–	–	0.76%	32
2020 Q2	$1.46M	Buy	13,000 +4,000	+44%	+$425K	0.82%	32
2020 Q1	$808K	Buy	+9,000	New	+$883K	0.53%	35

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

DCF Advisers's ALXN Position: Q3 2021 in Review

DCF Advisers sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 6,000 shares — an estimated $1.1M sold.

DCF Advisers first reported a position in ALXN in Q1 2020 and held it in 6 quarters. The position peaked at $2.34M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

DCF Advisers reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
DCF Advisers sold 6,000 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1.1M.
DCF Advisers first reported a position in Alexion Pharmaceuticals in Q1 2020 and held it in 6 quarters.
DCF Advisers's Alexion Pharmaceuticals position peaked at $2.34M in Q4 2020.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on DCF Advisers's 13F filing for Q3 2021, filed 15 Nov 2021.